
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Surrozen Inc. Warrant (SRZNW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SRZNW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.57 | 52 Weeks Range 0.01 - 0.09 | Updated Date 05/20/2025 |
52 Weeks Range 0.01 - 0.09 | Updated Date 05/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -971.62% |
Management Effectiveness
Return on Assets (TTM) -21.41% | Return on Equity (TTM) -456.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5400593 |
Shares Outstanding - | Shares Floating 5400593 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Surrozen Inc. Warrant
Company Overview
History and Background
Surrozen, Inc. was a preclinical biopharmaceutical company focused on discovering and developing novel regenerative medicines with a focus on modulating the Wnt signaling pathway. The warrant (SRZN.WS) existed due to the company's public debut via a merger, and represents the right to purchase shares of Surrozen stock.
Core Business Areas
- Wnt Signaling Drug Development: Focused on developing therapies that stimulate the body's own repair mechanisms using Wnt signaling.
Leadership and Structure
Information about the leadership and organizational structure of Surrozen Inc. is limited since it ceased operations. It was previously a publicly traded company with a standard leadership team structure, prior to winding down.
Top Products and Market Share
Key Offerings
- SZN-1326: A potential treatment for severe alcoholic hepatitis and other liver diseases. Preclinical stage. Competitors include companies developing therapies for liver diseases, such as Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT), although their mechanisms differ from Surrozen's Wnt activation approach. It did not get to market.
- SZN-043: A potential treatment for inflammatory bowel disease (IBD). Preclinical stage. Competitors include companies developing IBD therapies, such as AbbVie (ABBV) and Takeda (TAK), although their mechanisms differ from Surrozen's Wnt activation approach. It did not get to market.
Market Dynamics
Industry Overview
The regenerative medicine industry is characterized by significant unmet need and high potential. The industry is highly competitive with both established pharmaceutical companies and smaller biotech firms pursuing novel therapeutic approaches.
Positioning
Surrozen aimed to position itself as a leader in Wnt signaling-based regenerative medicine. Given the company ceased operations, its positioning is now moot.
Total Addressable Market (TAM)
The TAM for regenerative medicine targeting liver diseases and IBD is substantial, estimated to be in the billions of dollars. Surrozen's Wnt-based approach sought to capture a portion of this market, but that will not be realized.
Upturn SWOT Analysis
Strengths
- Novel Wnt signaling technology platform
- Potential for regenerative medicine breakthroughs
Weaknesses
- Preclinical stage programs
- High cash burn rate
- Dependence on successful clinical trials
- Company Ceased operations
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Clinical trial failures
- Competition from other regenerative medicine approaches
- Regulatory hurdles
- Funding constraints
Competitors and Market Share
Key Competitors
Competitive Landscape
Surrozen faced competition from large and small pharmaceutical companies developing therapies for liver diseases and IBD. Its novel Wnt signaling approach offered a potential differentiator, but the company failed to overcome its challenges.
Growth Trajectory and Initiatives
Historical Growth: Surrozen Inc. did not achieve significant revenue or commercial success before ceasing operations.
Future Projections: No future projections are available since the company has ceased operations.
Recent Initiatives: Prior to its shutdown, Surrozen Inc. was focused on advancing its preclinical programs.
Summary
Surrozen Inc. was a preclinical biopharmaceutical company focused on regenerative medicine that ultimately ceased operations. While it possessed a novel Wnt signaling platform, it faced challenges in securing funding and advancing its programs through clinical trials. As a result, it was unable to capitalize on its potential and deliver value to shareholders. The warrants (SRZN.WS) became worthless, as the company was dissolved.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (prior to delisting)
- Financial News Outlets (prior to cessation of operations)
Disclaimers:
This analysis is based on publicly available information prior to the company's cessation of operations. The information provided is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Surrozen Inc. Warrant
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-08-12 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.surrozen.com |
Full time employees 40 | Website https://www.surrozen.com |
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.